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Abstract
Background:  Although carbapenems are the primary treatment 
strategy for invasive infections caused by ESBL bacteria, case re-
ports of these pathogens with reduced carbapenem susceptibility 
have emerged. One potential treatment modality is to optimize the 
use of anti-infectives with combination therapy. We evaluated the 
activity of carbapenems alone and in combination with amikacin 
against these clinical isolates.
Methods:  Time-kill studies evaluated ertapenem (ETP), imipenem 
(IPM), meropenem (MEM), and amikacin (AMK) against 4 non-
duplicate clinical isolates of Klebsiella pneumoniae that were resis-
tant to these antibiotics. Synergy was defined as ≥ 2 log10 decrease 
CFU/mL at 24 h for the combination when compared with the most 
active single agent of the combination, plus the number of surviv-
ing organisms for the antimicrobial combination was ≥ 2 log10 less 
than the initial inoculum.
Results:  All isolates carried blaKPC-3 and genes encoding TEM-1 
and SHV-11/-36; and were resistant to carbapenems (MIC at ≥ 8 
µg/mL for ETP, MEM and IPM) and AMK (MIC 32 µg/mL) us-
ing broth microdilution. As monotherapy, none of the carbapenems 
nor AMK achieved and maintained bactericidal activity defined as 
≥ 99.9% or > 3 log10 killing. From time-kill studies, synergy was 
demonstrated for MEM and IPM in combination with AMK over 
the entire 24 h against all isolates. In addition, MEM and IPM with 
AMK achieved and maintained bactericidal activity (≥ 99.9% kill-
ing) at 24 h against 2 and 1 isolate(s), respectively. Bactericidal 
activity and synergy were not observed for ETP combinations.
Conclusions:  The combination of MEM or IPM with AMK dis-
played synergistic activity against KPC-3-producing K. pneumoni-
ae isolates.
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Introduction
Carbapenems  are  the  primary  treatment  strategy  for  seri-
ous infections caused by extended-spectrum beta-lactamase 
(ESBL)-producing  Klebsiella  pneumoniae.  However,  pro-
duction of KPC β-lactamase, a serine carbapenemase pri-
marily detected in K. pneumoniae, has emerged in the USA 
and is probably contributing to carbapenem resistance rates 
among Enterobacteriaceae [1, 2].
In  light  of  this  carbapenem  resistance  and  with  the 
dearth of new antimicrobial agents with novel mechanisms 
of action, combination therapy using existing antibiotics be-
comes an attractive option. The combination of two antibiot-
ics from different classes will increase the probability that at 
least one antibiotic will provide adequate activity against the 
multi-drug resistance isolate and enhance their activity when 
synergy is present. This is crucial since inappropriate initial 
antimicrobial  therapy  has  been  associated  with  increased 
mortality [3-5].
Based on limited clinical experience, susceptibility data 
and  single  antibiotic  pharmacokinetic-pharmacodynamic 
studies,  polymixin  B  [6,  7],  tigecycline  [6-9], AMK  [6], 
carbapenems  [10-12],  and  clavulanic  acid  like  ticarcillin/
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clavulanate [13] may play a role in combination therapy for 
infections  caused  by  KPC-producing  pathogens.  We  per-
formed time-kill studies to evaluate the in vitro activity of 
carbapenems [including ertapenem (ETP), imipenem (IPM) 
and meropenem (MEM)] alone or in combination with ami-
kacin (AMK) against KPC-producing K. pneumoniae. These 
antibiotics were selected due to their safety profile and feasi-
bility to be used empirically since detection of KPC produc-
tion in clinical laboratory can be challenging. In addition, 
amikacin has a fast rate of bactericidal activity [14] and post-
antibiotic effect [15].
Materials and Methods
Drug stock solutions were prepared according to the manu-
facturer’s recommendations from powders of ETP (Astra-
Zeneca, Wilmington, DE), IPM (Merck, Whitehouse Sta-
tion, NJ), MEM (AstraZeneca, Wilmington, DE), and AMK 
(Bristol-Myers  Squibb,  New York,  NY).  Drug  concentra-
tions were based on the mean steady-state serum concentra-
tion obtained using normal doses of each antibiotic in normal 
healthy volunteers. The following antibiotics at the specified 
concentrations (µg/mL) were used: ETP 2, IPM 4, MEM 4, 
and AMK 16.
Four non-duplicate isolates of K. pneumoniae obtained 
from an observational clinical outcomes study carried blaK-
PC-3 and genes encoding TEM-1 and SHV-11/-36 [16]. Isolate 
number 16, 17, 38 and 50 corresponded to the following pa-
tients 1, 2, 4 and 3, respectively. Isolates were negative for 
all other beta-lactamase encoding genes, including plasmidic 
AmpC, serine- and metallo-β-lactamases, tested. Molecular 
typing demonstrated that all 4 KPC-3-producing strains were 
clonally related.
Using broth microdilution as described by the Clinical 
and Laboratory Standards Institute (CLSI), all strains were 
resistant to carbapenems (MIC at ≥ 8 µg/mL for ETP, MEM 
and IPM) and AMK (MIC 32 µg/mL). Likewise using E-
tests, MIC values of all carbapenems were ≥ 32 µg/mL for all 
isolates and AMK were 128, 32, 48 and 48 µg/mL for C16, 
C17, C38 and C50, respectively.
Time-kill studies were performed using a final volume 
of 25 mL of cation-adjusted Mueller-Hinton broth and an ini-
tial inoculum of ~ 1 × 106 CFU/mL. Samples were taken at 0, 
4, 8, 12 and 24 h. Fifty μL was plated on trypticase soy agar 
plates using a spiral plater (Spiral Biotech, Bethesda, MD) 
and then incubated at 35 °C for 24 h before colony counts 
were determined using a laser colony counter (CASBA 4, 
Spiral Biotech, Bethesda, MD). The spiral plater controlled 
antibiotic carry-over [17]. Time-kill profiles were construct-
ed (log CFU/mL versus time). The limit of quantification 
was 102 CFU/mL. Any colony count lower than this limit 
was rounded to 102 CFU/mL. All tests were performed in 
duplicate.
Results
The mean starting inoculum for all of the time-kill experi-
ments was 5.51 × 106 CFU/mL with an intra-day CV of < 
7.0%. As monotherapy, none of the carbapenems nor AMK 
achieved and maintained bactericidal activity defined as ≥ 
99.9% or > 3 log10 killing (Table 1). Maximum killing of ≥ 
90% was observed for MEM and AMK against all isolates; 
and IPM against 3 isolates (except C17). ETP alone was least 
active as it did not achieve ≥ 90% killing in any isolates. 
Antibacterial activity was not maintained since significant 
regrowth  was  observed  for  all  antibiotics  after  achieving 
90% killing against each of the isolates (Fig. 1). In particular, 
amikacin demonstrated regrowth after 8 hrs.
Time-kill  curve  results  for  each  carbapenem  in  com-
bination with AMK are depicted in Figure 1. Synergy was 
defined as ≥ 2 log10 decrease CFU/mL at 24 h for the com-
bination when compared with the most active single agent 
of the combination, plus the number of surviving organisms 
for the antimicrobial combination was ≥ 2 log10 less than the 
initial inoculum. Synergy was demonstrated for MEM and 
IPM in combination with AMK over the entire 24 h against 
all isolates. In addition, MEM and IPM with AMK achieved 
and maintained bactericidal activity (≥ 99.9% killing) at 24 
h against 2 isolates (C38 and C50) and 1 (C50), respectively. 
For these isolates C38 and C50, the time to bactericidal ac-
tivity were 12 h for MEM plus AMK and 24 and 8 h, respec-
tively, for IPM plus AMK.
Bactericidal activity and synergy were not observed for 
Table 1. Change in Colony Count (log10 CFU/mL) at 24 
Hours Compared to Initial Inoculums for KPC-3-Produc-
ing K. Pneumoniae Isolates Using Time-Kill Methodol-
ogy
Synergy denoted as *.
AMK: amikacin; ETP: ertapenem; IPM: imipenem; MEM: me-
ropenem.
Antibiotic C16 C17 C38 C50
Growth control 5.05 4.13 4.78 4.55
AMK 1.36 3.75 2.98 4.23
ETP 4.00 3.14 5.16 4.83
IPM 4.02 3.30 4.50 4.71
MEM 3.69 3.59 4.90 4.09
ETP + AMK 1.57 2.81 3.86 4.45
IPM + AMK -1.48* -0.05* -2.13* -3.53*
MEM + AMK -1.71* -2.61* -3.58* -3.07*
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ETP combinations. In addition, significant regrowth for ETP 
with AMK was evident for all isolates between 8 and 12 h. 
Slight regrowth occurred in 1 isolate (C16) for MEM and 3 
isolates (except C50) for IPM combinations at 24 h. None of 
the antibiotic combinations demonstrated antagonism, which 
was defined as ≥ 2 log10 increase in colony count at 24 h for 
the combination when compared with the most active single 
agent of the combination.
Discussion
  
The clinical utility of carbapenem monotherapy is limited 
against  isolates  that  produce  KPC  carbapenemases  [13]. 
Studies of prolonged infusion of high-dose regimens of beta-
lactams, particularly meropenem at 2 g every 8 hours over 
3-hours, against KPC isolates have produced conflicting re-
sults [18, 19]. Although rapid colony reduction was initially 
observed, regrowth occurred after 6 hr of meropenem expo-
sure. Furthermore, meropenem exposure (or the percent time 
of free drug concentration above the MIC) for KPC isolates 
with elevated MICs of 8 and 16 µg/mL was significantly re-
duced due to rapid in vitro hydrolysis [19].
In light of the emerging resistance to carbapenems and 
the  limited  utility  of  overcoming  this  resistance  through 
prolonged infusion of high-dose carbapenem monotherapy, 
combination therapy may play a role in the treatment of in-
fections associated with KPC production since it may provide 
the potential for synergistic effects between two different 
classes of anti-infectives [20]. Studies evaluating antibiotic 
combinations against KPC-harboring isolates are limited. In 
our study, MEM or IPM in combination with AMK displayed 
synergy against KPC-producing K. pneumoniae. In another 
study, synergy was observed in combinations of polymyxin 
B with rifampin, doxycycline or tigecycline [7, 21].
Conclusion
The addition of AMK to carbapenems, particularly MEM 
and IPM, provided synergistic effects and enhanced bacte-
ricidal activity against K. pneumoniae with reduced suscep-
tibility to carbapenems. Prolonged infusion of a high-dose 
carbapenem  in  combination  with  other  potentially  active 
antibiotics (such as AMK, tigecycline, and polymyxin B) 
may be a therapeutic option for serious infections associated 
with KPC production. Further investigation is warranted to 
determine if our in vitro observations translate into clinical 
efficacy. In addition, more research is imperative to optimize 
Figure 1. Time-kill studies of carbapenems and amikacin alone and in combination against four KPC-3-producing K. 
pneumoniae isolates. GC: Growth control; AMK: amikacin; ETP: ertapenem; IPM: imipenem; MEM: meropenem.
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the dosing regimens of currently approved antibiotics using 
pharmacokinetic-pharmacodynamic  principles  and  to  ex-
plore the potential role of novel chemical entities.
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